Literature DB >> 9624244

Co-variables influencing 5-fluorouracil clearance during continuous venous infusion. A NONMEM analysis.

M C Etienne1, E Chatelut, X Pivot, M Lavit, A Pujol, P Canal, G Milano.   

Abstract

The objective of this study was to attempt to identify patient co-variables which could influence interpatient variability in 5-fluorouracil (5-FU) clearance during a 5-day continuous venous infusion (CVI, cisplatin 100 mg/m2 day 1 then 5-FU 1 g/m2/day days 2-6). The analysis was performed using a NONMEM program according to a linear one-compartment model. A total of 186 cycles (2 samples per day, 8 a.m. and 5 p.m.) were analysed from 104 patients with various cancers (the majority of head and neck and oesophagus). The study co-variables were age, sex, body surface area, hepatic metastases, peripheral mononuclear cell dihydropyrimidine dehydrogenase activity (PMNC-DPD), liver enzymes, clock-time (8 a.m. versus 5 p.m.), elapsed time during CVI. The data showed that 5-FU clearance was significantly reduced by increased age, low PMNC-DPD, high serum alkaline phosphatase and elapsed time during infusion. These data may be useful for improving knowledge of predictive factors which can influence 5-FU exposure and thus predispose to toxic manifestations.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9624244     DOI: 10.1016/s0959-8049(97)00345-6

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  17 in total

1.  Clinical pharmacokinetics of oxaliplatin and 5-fluorouracil administered in combination with leucovorin in Korean patients with advanced colorectal cancer.

Authors:  Hea-Kyoung Cho; Eun-Sook Lee; Jung-Won Lee; Jong-Kook Park; Jin-Hyoung Kang; Kyung-Shik Lee; Chang-Koo Shim; Suk-Jae Chung; Dae-Duk Kim; Hyo-Jeong Kuh
Journal:  J Cancer Res Clin Oncol       Date:  2006-01-04       Impact factor: 4.553

Review 2.  Population pharmacokinetics and pharmacodynamics for treatment optimization in clinical oncology.

Authors:  Anthe S Zandvliet; Jan H M Schellens; Jos H Beijnen; Alwin D R Huitema
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

3.  Sirolimus population pharmacokinetic/pharmacogenetic analysis and bayesian modelling in kidney transplant recipients.

Authors:  Nassim Djebli; Annick Rousseau; Guillaume Hoizey; Jean-Philippe Rerolle; Olivier Toupance; Yann Le Meur; Pierre Marquet
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

4.  The impact of actual body weight-based chemotherapy dosing and body size on adverse events and outcome in older patients with breast cancer: Results from Cancer and Leukemia Group B (CALGB) trial 49907 (Alliance A151436).

Authors:  Vicki A Morrison; Linda McCall; Hyman B Muss; Aminah Jatoi; Harvey J Cohen; Constance T Cirrincione; Jennifer A Ligibel; Jacqueline M Lafky; Arti Hurria
Journal:  J Geriatr Oncol       Date:  2017-12-08       Impact factor: 3.599

5.  A phase I, dose-finding study of sunitinib combined with cisplatin and 5-fluorouracil in patients with advanced gastric cancer.

Authors:  C Gómez-Martín; R Salazar; C Montagut; M Gil-Martín; J A Núñez; M Puig; X Lin; R Khosravan; J M Tursi; M J Lechuga; J Bellmunt
Journal:  Invest New Drugs       Date:  2012-05-22       Impact factor: 3.850

Review 6.  The oral fluorinated pyrimidines.

Authors:  J S de Bono; C J Twelves
Journal:  Invest New Drugs       Date:  2001       Impact factor: 3.850

7.  Tacrolimus population pharmacokinetic-pharmacogenetic analysis and Bayesian estimation in renal transplant recipients.

Authors:  Khaled Benkali; Aurelie Prémaud; Nicolas Picard; Jean-Philippe Rérolle; Olivier Toupance; Guillaume Hoizey; Alain Turcant; Florence Villemain; Yannick Le Meur; Pierre Marquet; Annick Rousseau
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

8.  Pharmacokinetics and exposure-effect relationships of capecitabine in elderly patients with breast or colorectal cancer.

Authors:  Z Daher Abdi; S Lavau-Denes; A Prémaud; S Urien; F L Sauvage; J Martin; S Leobon; P Marquet; N Tubiana-Mathieu; A Rousseau
Journal:  Cancer Chemother Pharmacol       Date:  2014-05-07       Impact factor: 3.333

Review 9.  Practical treatment guide for dose individualisation in cancer chemotherapy.

Authors:  P Canal; E Chatelut; S Guichard
Journal:  Drugs       Date:  1998-12       Impact factor: 9.546

10.  Ciclosporin population pharmacokinetics and Bayesian estimation in thoracic transplant recipients.

Authors:  Dorothée Fruit; Annick Rousseau; Catherine Amrein; Florence Rollé; Nassim Kamar; Laurent Sebbag; Michel Redonnet; Eric Epailly; Pierre Marquet; Aurélie Prémaud
Journal:  Clin Pharmacokinet       Date:  2013-04       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.